Treatment of tissue in sphincters, sinuses, and orifices

Information

  • Patent Grant
  • 8740846
  • Patent Number
    8,740,846
  • Date Filed
    Monday, December 17, 2012
    12 years ago
  • Date Issued
    Tuesday, June 3, 2014
    10 years ago
Abstract
The invention comprises a method and apparatus for treatment of a body part. More particularly, a method and apparatus for heat treatment of tissue using a catheter inserted into a body part is described along with means for positioning the catheter and means for positioning a set of electrodes relative to a tissue sample for treatment. Still more particularly, radio frequency energy at about 400 to 500 kilohertz is used to provide heat for the tissue treatment.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


This invention relates to treatment of tissue, particularly in the sphincters, esophagus, sinuses and other internal body orifices and structures. Such treatment can be performed using ablation, coating, expansion, plumping, shaping, shrinking, or related techniques.


2. Related Art


Human beings are subject to a number of disorders in the sphincters, sinuses, esophagus and other internal orifices. Disorders in the rectum and colon include hemorrhoids (external and internal), fecal incontinence, prolapsed rectal muscles, rectal muscle spasms, anal fissures, polyps, diverticulosus, diverticulitus, and pilonital cysts. Other internal disorders in nearby regions of the male body include prostate cancer, blockage of the urethra and incontinence. Other internal disorders in nearby regions of the female body include incontinence, vaginal bleeding, vaginal cysts, vaginal fibroids, prolapsed uterus, and related tumors or cancerous tissue. Disorders of the pharynx include tumors and polyps in the hypopharynx, oropharynx and nasopharynx. Disorders in adjacent structures include Barrett's esophagus, laryngeal tumors and laryngeal polyps.


Known methods for the treatment of these disorders include surgery, pharmaceutical remedies, chemotherapeutic regimens, radiation, photodynamic therapy and lifestyle modification. These methods only occasionally achieve the goal of successful treatment of disorders in orifices, sphincters, esophagus and sinuses. Moreover, these methods suffer from several drawbacks.


Drawbacks to surgical treatment include its highly invasive nature, associated risks, possible iatrogenic effects, and high cost. Drawbacks to pharmaceutical and chemotherapeutic treatments include their relative ineffectiveness (particularly in the oral cavity and adjacent respiratory structures) and associated side effects. Moreover, these approaches are contraindicated for many patients. Drawbacks to lifestyle modification include relatively poor patient compliance and relative ineffectiveness. Drawbacks to photodynamic therapy include its frequent unavailability and limited applicability. Drawbacks to radiation include side effects such as exhaustion, radiation burns, chronic dry mouth and permanent distortion of the taste buds. Accordingly, it would be advantageous to provide techniques for treatment of these disorders that are not subject to these known drawbacks.


The use of radio frequency (RF) to ablate tissue in the body (such as heart muscle) is known in the art of cardiac treatment. However, known systems using RF energy are sill subject to several drawbacks. One known problem is that it can be difficult to block the flow of bodily fluids and gases into an area of the body where tissue ablation is taking place. Bodily fluids can dissipate and detrimentally absorb the energy to be applied to the tissue to be ablated. Dissipation of bodily fluids detracts from the goal of successful tissue ablation and etching.


A second known problem in the art involves directing and positioning the electrodes in the body cavity or orifice. Difficulties in accurately positioning the electrodes in the target orifice detract from treatment. Frequently, unhealthy tissue can remain unablated while healthy tissue is removed. Difficulties in directing and positioning the electrodes are particularly problematic because one of the goals of treatment is to minimize collateral damage to healthy tissue and to completely ablate diseased tissue.


A third known problem in the art involves difficulty in the simultaneous use of complimentary technology. Known systems do not provide for optimal, simultaneous use of auxiliary tools for visualization, feedback technology and drug administration.


Accordingly, it would be advantageous to provide improved techniques for treatment of disorders in the esophagus, sphincters, sinuses and other internal body orifices. For example, it would be advantageous to provide devices bearing different arrays of curvilinear electrodes that can be retracted or extended into the target tissue that can also support apparatus for drug administration and tissue visualization. Such devices would allow medical personnel to (1) visualize the tissue to be ablated or etched, (2) seal off the area from fluids and gases that would disturb the area to be ablated (3) ablate all diseased tissue while sparing healthy tissue and (4) provide for the localized administration of drugs to numb the area and treat the disorder. These advantages are achieved in an embodiment of the invention in which medical personnel use a catheter bearing multiple controls for visualization and drug administration, balloon-like air sacs for sealing the area and multiple arrays of curvilinear electrodes that can be extended and retracted as needed.


SUMMARY

The invention provides a method and system for treatment of body structures or tissue. The particular treatment can include one or more of, or some combination of ablation, coating, expansion, plumping, shaping, shrinking, or related techniques. The particular body structures or tissue can include one or more of, or some combination of regions, including a sphincter, sinus or orifice such as the rectum, colon, esophagus, vagina, penis, larynx or pharynx.


In one aspect of the invention, an environment proximate to or surrounding the targeted treatment region can be isolated or controlled by blocking the flow of gases or liquids using an inflatable balloon positioned immediately adjacent to the tissue that is to be ablated. The inflatable balloon can also serve to anchor the catheter in place and prevent the catheter from being expelled from the body. The inflatable balloon can also insure that locally administered drugs remain in the area where most needed.


In a second aspect of the invention, positive pressure is used to inflate the balloon. Inflation of the balloon triggers the extension of at least one curvilinear electrode into the targeted tissue. Negative pressure deflates the air sac and helps retract the curvilinear electrodes so as to allow the catheter to be removed from the body without damaging adjacent body structures. Alternately, the electrode(s) can be extended or retracted from the tissue, independently from the act of inflation or deflation of the balloon.


In a third aspect of the invention, the electrodes are coupled to sensors that measure properties of the target region, such as temperature and impedance. Measurement of these properties permits the use of feedback technique to control delivery of the RF energy and administration of fluids for cooling and hydrating the affected tissues. The electrodes can also be coupled to radio opaque markers to aid in fluoroscopic positioning.


In a fourth aspect of the invention, the catheter includes an optical path that can be coupled to external viewing apparatus. In this way, the position of the electrodes in the body can be determined using fiber optic techniques. The external viewing apparatus can also be coupled to an ultrasound probe included in the catheter.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a block diagram of a system for ablating tissue using a catheter and electrode assembly according to the invention;



FIG. 2 is a process flow diagram of a method for treatment for Barrett's esophagus according to the invention;



FIG. 3 is a process flow diagram of a method for treatment of fecal incontinence according to the invention;



FIG. 4 is a process flow diagram of a method for treatment of female urinary incontinence according to the invention;



FIG. 5 is a process flow diagram of a method for treatment of male urinary incontinence according to the invention;



FIG. 6 is a process flow diagram of a method for treatment of a hemorrhoid or pilonital cyst according to the invention; and



FIG. 7 is a process flow diagram of a method for treatment of an anal fissure according to the invention;



FIG. 8 shows an alternate embodiment of the apparatus of FIG. 1 according to the invention; and



FIG. 9 shows a balloon having micropores according to the invention.





DETAILED DESCRIPTION
System Elements


FIG. 1 is a block diagram of a system for ablating tissue associated with the rectal sphincter, esophagus, urethra and other internal body structures using a catheter and electrode assembly.


A catheter and electrode assembly 100 for treating tissue includes a catheter 110, an expandable cage structure 120 and a control and delivery linkage 130.


The catheter 110 includes a distal segment 111 and a proximal segment 112. The distal segment includes a tapered tip 113 for easy insertion into an orifice. The tapered tip 113 may be either flexible or rigid depending upon the orifice into which the catheter 110 is to be inserted. The overall length of the shaft of the catheter 110 (including the expandable cage structure 120) from the tapered tip 113 to the junction where the catheter 110 is coupled to the control and delivery linkage 120 is about 65 centimeters. The diameter of the catheter 110 is about 0.4 centimeters. In an alternative embodiment, the length and diameter of the shaft of the catheter 110 may vary substantially depending upon the application.


The catheter 110 includes an expandable cage structure 120. The cage structure 120 includes a set of struts 121, a set of curvilinear electrodes 122 and an inflatable balloon 123.


One end of each one of the struts 121 is coupled to the distal segment 111 of the catheter 110; the opposite end of each one of the set of struts 121 is coupled to the proximal segment 112 of the catheter. Taken together, the distal segment 111, the cage structure 120 and the proximal segment 112 are linearly contiguous and form one continuous unit. The inflatable balloon 123 is surrounded by the set of struts 121.


The set of curvilinear electrodes 122 is embedded in the set of struts 121. The electrodes 123 each include a metallic tube 124 defining a hollow lumen 125, shaped similarly to a curvilinear needle and a sensor 126. In addition to ablating tissue by delivering RF energy, the electrodes 113 are disposed to deliver at least one flowable substance to the area of the body where ablation is to take place. In a preferred embodiment, the flowable substance includes saline with a concentration of less than about 10% NaCl, which aids in hydration of body structures. However, in alternative embodiments, the deliverable flowable liquids includes other substances, including anesthetic drugs, anti-inflammatory agents, chemotherapeutic agents, systemic or topical antibodies, collagen and radioactive substances, such as labeled tracers.


Exact positioning of the electrodes 122 is achieved by inflating the balloon 123. Inflation of the balloon 123 causes expansion of the expandable cage structure 120, allowing one or more of the set of electrodes 122 to be extended directly into the targeted tissue.


The assembly 110 is operated by manipulating the control and delivery linkage 130. The control and delivery linkage 130 includes a port 131, two female couplings 132 and 133, a mechanical switch 135 and a hand set 136.


The port 131 can be coupled to both a RF source and a visualization apparatus, such as fiber optic devices or fluoroscopy equipment, to allow internal viewing of the orifice. The two female couplings 132 and 133 can be coupled to a syringe or other device to which positive pressure can be applied to inflate the balloon 123. In a preferred embodiment, one or more of the female couplings 132, 133 and 134 can also be coupled to drug administration apparatus. Manipulation of the mechanical switch 135 causes the extension of the electrodes 122. The female couplings 132, 133 and 134, mechanical switch 135 and port 131 are all located immediately adjacent to the hand set 136 to allow easy operation.


First Method of Operation



FIG. 2 is a process flow diagram of a method for treatment of Barrett's esophagus.


A method 200 is performed using a catheter and electrode assembly 100.


In a step 201, the tapered tip 113 of the catheter 110 is inserted into the oral cavity. Due to the potential for inducing pain or a gag reflex, the oral cavity is preferably pretreated with lidocaine spray or other topical anesthetic before insertion; depending upon the circumstances, a muscle relaxant may be indicated. In an alternative embodiment, the tapered tip 113 of the catheter 110 is inserted into a surgically created stoma.


The preferred size of the catheter 110 will be responsive to the orifice through which the catheter is inserted. The choice of pharmaceutical agents to be infused prior to or during treatment will be responsive to judgments by medical personnel, and may include lubricants, anesthetics, antispasmodics, anti-inflammatories, antibiotics or other agents.


In a step 202, the catheter 110 is threaded through the throat into the esophagus. Precautions are preferably taken to ensure that the catheter 110 is not threaded through the trachea into the lungs.


In a step 203, the catheter 110 is positioned near the Barrett's esophagus. In the preferred embodiment, viewing apparatus coupled to the port 131 may be used to examine the region and determine which specific tissues are targeted for ablation. Healthy tissue composed of white squamous cells is distinguished from unhealthy pink columnar cells indicative of Barrett's esophagus.


In a step 204, a syringe is connected to the female coupling 132, 133 or 134.


In a step 205, the syringe is used to exert positive pressure and inflate the balloon 123 with a flowable substance, such as air or liquid. Inflation of the balloon 123 serves several purposes. In addition to positioning the electrode 122, the balloon 123 also helps anchor the catheter 110 and prevents gas or liquids arising in the stomach from contaminating the region.


In a step 206, inflating of the balloon 123 causes expansion of the set of struts 121. Any corrections in the positioning of the catheter 110 are made at this time, using the visual apparatus coupled through the port 131.


In a step 207, one or more electrodes 122 are selected for extension into the columnar cells targeted for treatment. The particular treatment can include one or more of, or some combination of, ablation, coating, expansion, plumping, shaping, shrinking, or related techniques. The mechanical switch 134 is used to extend at least one electrode 122 into the targeted columnar cells.


In a step 208, RF energy is provided to the electrodes so as to ablate the targeted columnar cells. In a preferred embodiment, the RF energy has a frequency between 435 and 485 kilohertz. The tissue immediately near the electrodes receives the RF energy. The strength and duration of time the energy is applied are responsive to judgments by medical personnel. In alternative embodiments, the electrodes may deliver other forms of energy, such as heat, microwaves, infrared or visible laser energy. In other alternative embodiments, the electrodes are controlled by a feedback technique using at least one sensor 126, such as an impedance or temperature sensor.


To perform ablation, the tissue is heated for a short period of time until ablation occurs. Application of RF energy causes cell death by dehydration or denaturation of cellular proteins.


To perform expansion, plumping, or shaping, the tissue is suffused with a flowable substance, such as a gas or liquid, a collagen, or another substance that can be absorbed by the body structure or tissue. The flowable substance can be exuded from the catheter, either using a separate flow line, or using the electrodes themselves. In a preferred embodiment, the tissue is heated for a short time, and thereafter cooled, so as to cause the flowable substance to crosslink or otherwise transform into a bulking, plumping, or shaping agent.


To perform coating, the flowable substance can be exuded so as to adhere to (or be adsorbed by) an epithelial layer of cells. In a preferred embodiment, the tissue is heated for a short time, and thereafter cooled, so as to cause the flowable substance to crosslink or otherwise transform into a solid mass coating or covering the epithelial layer.


To perform shrinking, the tissue is suffused with the flowable substance, with the flowable substance being selected so as to act as a receiving antenna or dielectric for the RF energy. RF energy is applied, which is differentially absorbed by the flowable substance; this causes the flowable substance to heat and to shrink the tissue is suffused, either by cell death, dehydration, or denaturation of cellular proteins.


In a step 209, flowable substances are provided through the holes in the electrodes 122, the micropores of the balloon 123 or from the struts 121, if needed to immediately cool down the region and prevent collateral thermal damage. The nature, temperature and amount of the flowable substance are responsive to judgments by medical personnel.


In a step 210, the electrodes 122 are retracted back into the set of struts 121.


In a step 211, the balloon is deflated by negative pressure on the syringe. Deflation of the balloon 123 causes the expandable cage structure 120 to collapse.


In a step 212, the catheter 110 is withdrawn from the oral cavity. In an alternative embodiment, the catheter 110 is withdrawn from a stoma.


Second Method of Operation



FIG. 3 is a process flow diagram of a method for treatment of fecal incontinence.


A method 300 is performed using a catheter and electrode assembly 100. This method requires the use of four to eight electrodes and a blunt tapered tip 113.


In a step 301, an enema is performed to clear the region of fecal matter. The rectum and surrounding area are washed with a cleansing agent, such as benzalonium chloride. A topical anesthetic may be applied to prevent pain associated with insertion; depending upon the circumstances, a muscle relaxant may be indicated. The tapered tip 113 of the catheter 110 is inserted into the anus.


The preferred size of the catheter 110 will be responsive to the orifice through which the catheter is inserted. The choice of pharmaceutical agents to be infused prior to or during treatment will be responsive to judgments by medical personnel, and may include lubricants, anesthetics, antispasmodics, anti-inflammatories, antibiotics or other agents.


In a step 302, the catheter 110 is threaded into the anus so that the electrodes 122 are positioned neat the dentate line.


In a step 303, the catheter 110 is positioned neat the area to be treated. In the preferred embodiment, viewing apparatus, such as an anoscope coupled to port 131 may be used to examine the region and determine which specific tissues are targeted for ablation. In an alternative embodiment, the area can be accessed using a colorectal ultrasound probe. It is important to distinguish between the voluntary and involuntary sphincter because fecal incontinence is frequently causes by defects in the involuntary sphincter. One of the goals of treatment is to avoid exacerbating the incontinence problem by injuring the voluntary sphincter.


In a step 304, a syringe is connected to the female coupling 132, 133 or 134.


In a step 305, the syringe is used to exert positive pressure and inflate the balloon 123 with air or with a liquid. Inflation of the balloon 123 serves several purposes. In addition to positioning the electrode 122, the balloon 123 also helps anchor the catheter 110 and prevents gas, liquid or fecal matter from contaminating the region. If necessary, a second balloon can be used to anchor the catheter distally.


In a step 306, inflation of the balloon 123 causes expansion of the set of struts 121. Any corrections in the positioning of the catheter 110 are made at this time, using the visual apparatus coupled through the port 131.


In a step 307, four or more electrodes 122 are selected for extension into the involuntary sphincter. The mechanical switch 135 is used to extent the electrodes 122 into the involuntary sphincter. Thermal injury to sensitive female structures is avoided by selecting electrodes 122 in area other than the anterior portion of the anus. In both sexes, treatment is directed to the area one to two centimeter above and up to one centimeter below the dentate line. Highly innervated regions of tissue are avoided so as to minimize pain.


In a step 308, RF energy is provided to the electrodes until thermal lesions are created in the targeted area(s). In a preferred embodiment, the RF energy has a frequency between 435 kilohertz and 485 kilohertz. The RF energy is received by the tissue immediately near the electrodes. The tissue is heated for a short period of time until ablation occurs. Application of RF energy causes cell death by dehydration and denaturization of cellular proteins. The strength and duration of time the energy is applied are responsive to judgments by medical personnel.


In alternative embodiments, the electrodes may deliver other forms of energy, such as heat, microwaves, infrared or visible laser energy. In other alternative embodiments, the electrodes are controlled by a feedback technique using at least one sensor 126, such as an impedance or temperature sensor.


In a step 309, flowable substance are provided through holes in the electrodes 122, the struts 121 or the micropores of the balloon 123 if needed to immediately cool down the region and prevent collateral thermal damage. The nature, temperature and amount of the flowable substance are responsive to judgments by medical personnel.


In a step 310, the electrodes 122 are retracted back into the set of struts 121.


In a step 311, the balloon 123 is deflated by negative pressure on the syringe. Deflation of the balloon 123 causes the expandable cage structure 120 to collapse.


In a step 312, the catheter is withdrawn from the anus.


Third Method of Operation



FIG. 4 is a process flow diagram of a method for treatment for female urinary incontinence.


A method 400 is performed using a catheter and electrode assembly 100.


In a step 401, the area around the urethral meatus is cleansed. The tapered tip of the catheter 110 is well lubricated and introduced into the urethral meatus in an upward and backward direction, in much the same way one would introduce a Foley catheter. Due to the potential for inducing pain, the outer opening of the urethra may be pretreated with a topical anesthetic before treatment. The choice of pharmaceutical agents to be infuse prior to or during treatment will be responsive to judgments by medical personnel and may include lubricants, anesthetics, antispasmodics, anti-inflammatories, antibiotics or other agents.


In a step 402, the catheter 110 is threaded through the urethra until the tapered tip 113 reaches the neck of the bladder using strict aseptic technique.


In a step 403, viewing apparatus coupled to part 131 may be used to examine the region and determine which area of the urethral sphincter is targeted for treatment. Ultrasound or fluoroscopy can also be used for positioning.


In a step 404, a syringe is connected to the female coupling 132, 133 or 134 included in the control and delivery linkage 130.


In a step 405, the syringe is used to exert positive pressure and inflate the balloon 123 with air or liquid. Inflation of the balloon 123 serves several purposes. In addition to positioning the electrode 122, the balloon 123 also helps anchor the catheter 110. In an alternative embodiment, a second balloon 123 is used to help position the bladder neck and seal it off.


In a step 406, vacuum can be added to conform the tissue to the electrodes. This step is particularly advantageous for patients whose pelvic floor muscles are in poor condition. This step is optional.


In a step 407, inflation of the balloon 123 causes expansion of the expandable cage structure 120. Expansion of the cage structure brings the electrodes 122 into immediate contact with the urinary sphincter. Any correction to the position of the catheter 110 is made at this time, using the visual apparatus coupled through part 131.


In a step 408, one or more electrodes 122 are selected for extension into tissue targeted for ablation. The mechanical switch 135 is used to extend at least one electrode 122 into the targeted tissue.


In a step 409, RF energy is provided to the electrodes to create lesions on the targeted tissue. In a preferred embodiment, the RF energy has a frequency between 435 and 485 kilohertz. The RF energy is received by the tissue immediately near the electrodes for a period of time less than ten minutes. The device can be repositioned by rotation or translation so the RF energy is delivered to multiple sites to create a pattern of lesions over several centimeters of tissue. The duration of time and frequency of energy are responsive to judgments of medical personnel. Creation of these lesions has the effect of causing the involuntary sphincter to shrink so that urine does not seep through. In alternative embodiments, muscle contraction can be achieved by application of chemical stimulation.


In a step 410, flowable substances are provided through holes in the electrodes 122, the struts 121 and/or micropores of the balloon 123, if needed, to lower the temperature of the region and prevent collateral thermal damage. The nature, temperature and amount of flowable substance are responsive to judgments by medical personnel.


In a step 411, the electrodes 122 are retracted back into the set of struts 121.


In a step 412, the balloon 123 is deflated by application of negative pressure on the syringe. Deflation of the balloon 123 causes collapse of the expandable cage structure 120.


In a step 413, the catheter 110 is withdrawn from the urethra.


Fourth Method of Operation



FIG. 5 is a process flow diagram of a method for treatment of male urinary incontinence.


A method 500 is performed using a catheter and electrode assembly 100.


In a step 501, the tapered tip 113 of the catheter 110 is well lubricated. The area of the glans penis around the urinary meatus is washed with a cleansing agent such as benzalonium chloride. Due to the potential for inducing pain, the area surrounding the urinary means may be pretreated with a topical anesthetic before insertion; depending upon the circumstances, a muscle relaxant may be indicated.


The preferred size of the catheter 110 will be responsive to the orifice through which the catheter is inserted. The choice of pharmaceutical agents to be infused prior to or during treatment will be responsive to judgments by medical personnel, and may include lubricants, anesthetics, antispasmodics, anti-inflammatories, antibiotics or other agents.


In a step 502, the catheter 110 is introduced into the urethra along the anterior wall. The catheter is advanced 17.5-25 centimeters. Since the length from the bladder to the end of the glans penis varies, the distance that the catheter is advanced in responsive to the judgment of medical personnel.


In a step 503, the catheter 110 is positioned near the target area for treatment. In the preferred embodiment, viewing apparatus coupled to the port 131 may be used to examine the region and determine which specific tissues are targeted for treatment.


In a step 504, a syringe is connected to the female coupling 132, 133 or 134.


In a step 505, the syringe is used to exert positive pressure and inflate the balloon 123 with air or liquid. Inflation of the balloon 123 serves several purposes. In addition to positioning the electrode 122, the balloon 123 also helps anchor the catheter 110. If necessary, a second balloon 123, located distally, can also be inflated to anchor the balloon 123 in the bladder.


In a step 506, inflation of the balloon 123 causes expansion of the set of struts 121. Any corrections in the positioning of the catheter 110 are made at this time, using the visual apparatus coupled through port 131.


In a step 507, one or more electrodes 122 are selected for extension. The mechanical switch 135 is used to extend at least one electrode into the targeted tissue.


In a step 508, RF energy is provided to the electrodes so as to create lesions upon targeted regions of the urethra and bladder. In a preferred embodiment, the RF energy has a frequency between 435 and 485 kilohertz. The RF energy is received by the tissue immediately near the electrodes. The device can be repositioned by rotation or translation so that RF energy is delivered to multiple sites to create a pattern of lesions over several centimeters of tissue. Creation of these lesions has the effect of causing the involuntary sphincter to shrink so that urine does not seep through. In alternative embodiments, muscle contraction (and the consequence shrinkage of the involuntary sphincter) can be achieved by application of chemical stimulation. In other alternative embodiments, the electrodes are controlled by a feedback technique using at least one sensor 126, such as an impedance or temperature sensor.


In a step 509, flowable substances are provided through the holes in the electrodes 122, the struts 121 and/or the micropores in the balloon 123 if needed to immediately cool down the region and prevent collateral thermal damage. The nature, temperature and amount of the flowable substance are responsive to judgments by medical personnel.


In a step 510, the electrodes 122 are retracted back into the set of struts 121.


In a step 511, the balloon 123 is deflated by negative pressure on the syringe. Deflation of the balloon 123 causes the expandable cage structure 120 to collapse.


In a step 512, the catheter 110 is withdrawn from the glans penis.


Fifth Method of Operation



FIG. 6 is a process flow diagram of a method for treatment of a hemorrhoid.


A method 600 is performed using a catheter and electrode assembly 100.


In a step 601, the tapered tip 113 of the catheter 110 is well lubricated. An enema is performed to clear the area of fecal matter. The rectum and surrounding area are washed with a cleansing agent such as benzalonium chloride. Due to the potential for inducing pain, the area surrounding the rectum may be presented with a topical anesthetic before insertion; depending upon the circumstances, a muscle relaxant may be indicated.


The preferred size of the catheter 110 will be responsive to the orifice through which the catheter is inserted. The choice of pharmaceutical agents to be infused prior to or during treatment will be responsive to judgments by medical personnel, and may include lubricants, anesthetics, antispasmodics, anti-inflammatories, antibiotics or other agents.


In a step 602, the catheter 110 is introduced into the anus and advanced along the walls of the sphincter. Since hemorrhoids and pilonital cysts may occur anywhere along this passage, the distance that the catheter is introduced is responsive to the judgment of medical personnel.


In a step 603, the catheter is positioned near the internal hemorrhoid, external hemorrhoid or cyst that is targeted for ablation. In the preferred embodiment, viewing apparatus coupled to the port 131 may be used to examine the region and determine which specific tissues are targeted for ablation. Ultrasound or fluoroscopy may also be employed to help position the catheter 110.


In a step 604, a syringe is connected to the female coupling 132, 133 or 134.


In a step 605, the syringe is used to exert positive pressure and inflate the balloon 123 with air or with a liquid. Inflation of the balloon 123 serves several purposes. In addition to positioning the electrode 122, the balloon 123 also helps anchor the catheter 110, seal off the region and prevent contamination with fecal matter.


In a step 606, inflation of the balloon 123 causes expansion of the set of struts 121. Any corrections in the positioning of the catheter 110 are made at this time, using the visual apparatus coupled through port 131.


In a step 607, one or more electrodes 122 are selected for extension. The mechanical switch 135 is used to extend at least one electrode 122 into the targeted tissue.


In a step 608, RF energy is provided to the electrodes so as to ablate the hemorrhoid or cyst. In a preferred embodiment, the RF energy has a frequency between 435 and 485 kilohertz. The RF energy is received by the tissue immediately near the electrodes. The tissue is heated for a short period of time until ablation occurs. In an alternative embodiment, the electrodes are controlled by a feedback technique using at least one sensor 126, such as an impedance or temperature sensor.


In a step 609, flowable substances are provided through the holes in the electrodes 122, the struts 121 and/or the micropores of balloon 123 if needed to immediately cool down the region and prevent collateral thermal damage. The nature, temperature and amount of the flowable substance are responsive to judgments by medical personnel.


In a step 610, the electrodes 122 are retracted back into the set of struts 121.


In a step 611 the balloon 123 is deflated by negative pressure on the syringe. Deflation of the balloon 123 causes the expandable cage structure 120 to collapse.


Steps 605 through 611 are repeated as necessary until all hemorrhoids or cysts are removed.


In a step 612, the catheter 110 is withdrawn from the anus.


Sixth Method of Operation



FIG. 7 is a process flow diagram of a method for treatment of an anal fissure.


A method 700 is performed using a catheter and electrode assembly 100.


In a step 701, the tapered tip 113 of the catheter 110 is well lubricated. An enema is performed to clear the region of fecal matter. The anus and rectal area are washed with a cleansing agent such as benzalonium chloride. Due to the potential for inducing pain, the area surrounding the anus may be pretreated with a topical anesthetic before insertion; depending upon the circumstances, a muscle relaxant may be indicated.


The preferred size of the catheter 110 will be responsive to the orifice through which the catheter is inserted. The choice of pharmaceutical agents to be infused prior to or during treatment will be responsive to judgments by medical personnel, and may include lubricant, anesthetics, antispasmodics, anti-inflammatories, antibiotics or other agents.


In a step 702, the catheter 110 is introduced into the anus and advanced along the walls of the sphincter. The distance that the catheter 110 is introduced is responsive to the judgment of medical personnel.


In a step 703, the catheter 110 is positioned near an anal fissure. In the preferred embodiment, viewing apparatus coupled to the port 131 may be used to examine the region and determine which specific tissues are targeted for ablation and where collagen should be deposited. Ultrasound or fluoroscopic imaging can also be used to position the catheter 110.


In a step 704, a syringe is connected to the female coupling 132, 133 or 134.


In a step 705, the syringe is used to exert positive pressure and inflate the balloon 123 with air or with a liquid. Inflation of the balloon 123 serves several purposes. In addition to positioning the electrode 122, the balloon 123 also helps anchor the catheter 110. In an alternative embodiment, a second balloon 123 can be inflated, if necessary to help anchor the catheter 110.


In a step 706, inflation of the balloon 123 causes expansion of the set of struts 121. Any corrections in the position of the catheter 110 are made at this time, using the visual apparatus coupled through port 131.


In a step 707, one or more electrodes 122 are selected for extension. The mechanical switch 135 is used to extend at least one electrode 122 into the targeted tissue.


In a step 708, collagen is deposited into the fissure.


In a step 709, RF energy is provided to the electrodes so as to harden the collagen for filling the fissure. In a preferred embodiment, the RF energy has a frequency between 435 kilohertz and 485 kilohertz. The RF energy is received by the tissue immediately near the electrodes. The tissue is heated for a short period of time until the collagen is sufficiently hardened. In an alternative embodiment, the electrodes are controlled by a feedback technique using at least one sensor 126, such as an impedance or temperature sensor.


In a step 710, other flowable substances are provided through the holes in the electrodes 122, the struts 121 and/or the micropores of the balloon 123, if needed to immediately cool down the region and prevent collateral damage. The nature, temperature and amount of the flowable substance are responsive to judgments by medical personnel.


In a step 711, the electrodes 122 are retracted back into the set of struts 121.


In a step 712, the balloon 123 is deflated by negative pressure on the syringe. Deflation of the balloon 123 causes the expandable cage structure 120 to collapse.


In a step 713, the catheter 110 is withdrawn from the anus.


Alternative Embodiments

Although preferred embodiments are disclosed herein, many variations are possible which remain within the concept, scope and spirit of the invention, and these variations would become clear to those skilled in the art after perusal of this application.

Claims
  • 1. A method of tissue heat treatment of urinary incontinence in a woman, comprising the steps of: inserting a catheter into the womans's urethra, said catheter comprising: a set of electrodes configured to extend into the tissue targeted for heat treatment,wherein the step of inserting the catheter comprises threading said catheter through the woman's urethra until a tapered tip of the catheter and deflated balloon reaches the bladder using strict aseptic technique;extending the electrodes through the urethra and into the tissue; anddelivering electromagnetic energy to said tissue from the electrodes, wherein said electromagnetic energy comprises radio frequency energy.
  • 2. The method of claim 1, wherein said set of electrodes comprises four to eight electrodes.
  • 3. The method of claim 2, wherein said set of electrodes comprises four electrodes.
  • 4. The method of claim 1, wherein the step of extending comprises operating a mechanical control integrated into said catheter.
  • 5. The method of claim 1, further comprising the step of: anchoring said catheter through inflation of a balloon attached to said catheter.
  • 6. The method of claim 5, further comprising the step of: anchoring the catheter at or near the neck of the bladder.
  • 7. The method of claim 1, further comprising the step of: repositioning said catheter by rotation.
  • 8. The method of claim 1, further comprising the step of: repositioning said catheter by translation to deliver electromagnetic energy to multiple target regions.
  • 9. The method of claim 1, wherein said radio frequency energy comprises energy at about 400 to 500 kilohertz.
  • 10. The method of claim 9, wherein said step of delivering electromagnetic energy comprises a period of less than about ten minutes.
  • 11. The method of claim 10, further comprising the step of: introducing said catheter through a urethra into a bladder.
  • 12. The method of claim 1, wherein said catheter comprises a tapered tip, wherein said tapered tip is at least one of flexible and rigid.
  • 13. The method of claim 1, wherein said step of delivering radio frequency energy comprises denaturing of cellular proteins.
  • 14. The method of claim 1, wherein said step of extending the electrodes is independent from a step of anchoring said catheter.
  • 15. The method of claim 1, wherein said set of electrodes surround a central axis.
  • 16. The method of claim 15, further comprising the step of: firmly holding said catheter relative to said tissue sample.
  • 17. The method of claim 16, wherein said set of electrodes comprises a set of about four to eight electrodes.
  • 18. The method of claim 1, wherein said catheter comprises a blunt tapered tip.
  • 19. The method of claim 1, further comprising the step of: cooling said tissue sample.
  • 20. The method of claim 19, wherein said step of cooling comprises the step of: delivering a flowable substance about said tissue sample, wherein said flowable substance prevents collateral thermal damage.
  • 21. The method of claim 20, wherein said step of delivering a flowable substance is simultaneous with said step of delivering electromagnetic energy.
  • 22. The method of claim 1, further comprising the step of: anchoring said catheter with a balloon.
  • 23. The method of claim 1, further comprising the step of: lubricating said tapered tip prior to said step of threading.
  • 24. The method of claim 1, further comprising any of the steps of: washing an area around the urinary meatus; andpretreating an area around at least a portion of said urinary meatus with a topical anesthetic before insertion.
  • 25. A method of tissue heat treatment of urinary incontinence in a woman, comprising the steps of: inserting a catheter into the womans's urethra, said catheter comprising: a set of electrodes configured to extend into the tissue targeted for heat treatment;introducing said catheter through a urethra into a bladder;extending the electrodes through the urethra and into the tissue; anddelivering electromagnetic energy to said tissue from the electrodes, wherein said electromagnetic energy comprises radio frequency energy comprising energy at about 400 to 500 kilohertz, having a period of less than about ten minutes.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/648,249 filed Dec. 28, 2009, which is a division of U.S. patent application Ser. No. 11/207,677, filed Aug. 18, 2005, which is a continuation of U.S. patent application Ser. No. 09/356,110 filed Jul. 16, 1999, now U.S. Pat. No. 7,022,105, which is a continuation-in-part of U.S. patent application Ser. No. 08/717,612 filed Sep. 20, 1996, now U.S. Pat. No. 6,077,257, all of which are included by reference herein in their entireties.

US Referenced Citations (331)
Number Name Date Kind
1798902 Raney Mar 1931 A
3011684 Cornell Dec 1961 A
3353491 Bastian Nov 1967 A
3517128 Hines Jun 1970 A
3597124 Adams Aug 1971 A
3901241 Allen, Jr. Aug 1975 A
4011872 Komiya Mar 1977 A
4138205 Wallach Feb 1979 A
4187057 Xanthopoulos Feb 1980 A
4196724 Wirt et al. Apr 1980 A
4311154 Sterzer et al. Jan 1982 A
4411266 Cosman Oct 1983 A
4423812 Sato Jan 1984 A
4532924 Auth et al. Aug 1985 A
4552516 Stanley Nov 1985 A
4565200 Cosman Jan 1986 A
4568255 Lavender et al. Feb 1986 A
4587975 Salo et al. May 1986 A
4673393 Suzuki et al. Jun 1987 A
4674506 Alcond Jun 1987 A
4705041 Kim Nov 1987 A
4708604 Kidera Nov 1987 A
4742829 Law et al. May 1988 A
4813855 Leveen et al. Mar 1989 A
4832688 Sagae et al. May 1989 A
4838506 Cooper Jun 1989 A
4846818 Keldahl et al. Jul 1989 A
4878492 Sinofsky et al. Nov 1989 A
4901737 Toone Feb 1990 A
4906203 Margrave et al. Mar 1990 A
4907589 Cosman Mar 1990 A
4925376 Kahler May 1990 A
4943290 Rexroth et al. Jul 1990 A
4946443 Hauser et al. Aug 1990 A
4947842 Marchosky et al. Aug 1990 A
4955377 Lennox et al. Sep 1990 A
4966597 Cosman Oct 1990 A
4976711 Parins et al. Dec 1990 A
4994033 Shockey et al. Feb 1991 A
4994069 Ritchart et al. Feb 1991 A
5002558 Klein et al. Mar 1991 A
5007897 Kalb et al. Apr 1991 A
5019075 Spears et al. May 1991 A
5035696 Rydell Jul 1991 A
5045078 Asta Sep 1991 A
5046512 Murchie Sep 1991 A
5047028 Qian Sep 1991 A
5049132 Shaffer et al. Sep 1991 A
5083565 Parins Jan 1992 A
5084044 Quint Jan 1992 A
5088522 Rath et al. Feb 1992 A
5088979 Filipi et al. Feb 1992 A
5090424 Simon et al. Feb 1992 A
5092841 Spears Mar 1992 A
5094233 Brennan Mar 1992 A
5100423 Fearnot Mar 1992 A
5100429 Sinofsky et al. Mar 1992 A
5102390 Crittenden et al. Apr 1992 A
5106360 Ishiwara et al. Apr 1992 A
5110270 Morrick May 1992 A
5122137 Lennox Jun 1992 A
5151909 Davenport et al. Sep 1992 A
5156151 Imran Oct 1992 A
5188596 Condon et al. Feb 1993 A
5190540 Lee Mar 1993 A
5190541 Abele et al. Mar 1993 A
5197963 Parins Mar 1993 A
5197964 Parins Mar 1993 A
5199951 Spears Apr 1993 A
5205287 Erbel et al. Apr 1993 A
5209776 Bass et al. May 1993 A
5213580 Slepian et al. May 1993 A
5215103 Desai Jun 1993 A
5215450 Tamari Jun 1993 A
5219335 Willard et al. Jun 1993 A
5219355 Parodi et al. Jun 1993 A
5232444 Just et al. Aug 1993 A
5236413 Feiring Aug 1993 A
5239982 Trauthen Aug 1993 A
5239999 Imran Aug 1993 A
5242441 Avitall Sep 1993 A
5243615 Ortiz et al. Sep 1993 A
5254126 Filipi et al. Oct 1993 A
5256138 Burek et al. Oct 1993 A
5257451 Edwards et al. Nov 1993 A
5263493 Avitall Nov 1993 A
5273535 Edwards et al. Dec 1993 A
5275162 Edwards et al. Jan 1994 A
5275608 Forman et al. Jan 1994 A
5275610 Eberbach Jan 1994 A
5277201 Stern Jan 1994 A
5278201 Dunn et al. Jan 1994 A
5281216 Klicek Jan 1994 A
5281217 Edwards et al. Jan 1994 A
5281218 Imran Jan 1994 A
5286254 Shapland et al. Feb 1994 A
5292321 Lee Mar 1994 A
5293869 Edwards et al. Mar 1994 A
5304214 DeFord et al. Apr 1994 A
5309910 Edwards et al. May 1994 A
5313943 Houser et al. May 1994 A
5314466 Stern et al. May 1994 A
5316020 Truffer May 1994 A
5318531 Leone Jun 1994 A
5322503 Desai Jun 1994 A
5324284 Imran Jun 1994 A
5324288 Billings et al. Jun 1994 A
5328467 Edwards et al. Jul 1994 A
5328471 Slepian Jul 1994 A
5334196 Scott et al. Aug 1994 A
5334201 Cowan Aug 1994 A
5336222 Durgin, Jr. et al. Aug 1994 A
5340290 Clemens Aug 1994 A
5342181 Schock et al. Aug 1994 A
5342357 Nardella Aug 1994 A
5344435 Turner et al. Sep 1994 A
5345936 Pomeranz et al. Sep 1994 A
5348554 Imran et al. Sep 1994 A
5349825 Duke et al. Sep 1994 A
5354279 Hofling Oct 1994 A
5363861 Edwards et al. Nov 1994 A
5365926 Desai Nov 1994 A
5365945 Halstrom Nov 1994 A
5368557 Nita et al. Nov 1994 A
5368592 Stern et al. Nov 1994 A
5370675 Edwards et al. Dec 1994 A
5370678 Edwards et al. Dec 1994 A
5374261 Yoon Dec 1994 A
5383876 Nardella Jan 1995 A
5383917 Desai et al. Jan 1995 A
5385544 Edwards et al. Jan 1995 A
5388972 Calhoun et al. Feb 1995 A
5398683 Edwards et al. Mar 1995 A
5400783 Pomeranz et al. Mar 1995 A
5401272 Perkins Mar 1995 A
5403311 Abele et al. Apr 1995 A
5405322 Lennox et al. Apr 1995 A
5405369 Selman et al. Apr 1995 A
5409000 Imran Apr 1995 A
5409453 Lundquist et al. Apr 1995 A
5409483 Campbell et al. Apr 1995 A
5415657 Taymor-Luria May 1995 A
5421819 Edwards et al. Jun 1995 A
5423744 Gencheff et al. Jun 1995 A
5423808 Edwards et al. Jun 1995 A
5423812 Ellman et al. Jun 1995 A
5428486 Nagase Jun 1995 A
5433720 Faccioli et al. Jul 1995 A
5433739 Sluijter et al. Jul 1995 A
5435805 Edwards et al. Jul 1995 A
5441499 Fritzsch Aug 1995 A
5443470 Stern et al. Aug 1995 A
5447417 Kuhl et al. Sep 1995 A
5448990 De Faria-Correa Sep 1995 A
5454782 Perkins Oct 1995 A
5454807 Lennox et al. Oct 1995 A
5456662 Edwards et al. Oct 1995 A
5456682 Edwards et al. Oct 1995 A
5458568 Racchini et al. Oct 1995 A
5458596 Lax et al. Oct 1995 A
5458597 Edwards et al. Oct 1995 A
5464395 Faxon et al. Nov 1995 A
5464404 Abela et al. Nov 1995 A
5465717 Imran et al. Nov 1995 A
5470308 Edwards et al. Nov 1995 A
5470309 Edwards et al. Nov 1995 A
5471982 Edwards et al. Dec 1995 A
5472441 Edwards et al. Dec 1995 A
5480417 Hascoet et al. Jan 1996 A
5484400 Edwards et al. Jan 1996 A
5485849 Panescu et al. Jan 1996 A
5486161 Lax et al. Jan 1996 A
5490984 Freed Feb 1996 A
5496271 Burton et al. Mar 1996 A
5496311 Abele et al. Mar 1996 A
5498238 Shapland et al. Mar 1996 A
5499971 Shapland et al. Mar 1996 A
5500012 Brucker et al. Mar 1996 A
5505730 Edwards Apr 1996 A
5507743 Edwards et al. Apr 1996 A
5514130 Baker May 1996 A
5514131 Edwards et al. May 1996 A
5514669 Selman May 1996 A
5520684 Imran May 1996 A
5531676 Edwards et al. Jul 1996 A
5536267 Edwards et al. Jul 1996 A
5540655 Edwards et al. Jul 1996 A
5542915 Edwards et al. Aug 1996 A
5542916 Hirsch et al. Aug 1996 A
5545161 Imran Aug 1996 A
5545171 Sharkey et al. Aug 1996 A
5545193 Fleischman et al. Aug 1996 A
5545434 Huarng Aug 1996 A
5549108 Edwards et al. Aug 1996 A
5549644 Lundquist et al. Aug 1996 A
5554110 Edwards et al. Sep 1996 A
5556377 Rosen et al. Sep 1996 A
5558672 Edwards et al. Sep 1996 A
5558673 Edwards et al. Sep 1996 A
5562720 Stern et al. Oct 1996 A
5569241 Edwards Oct 1996 A
5571116 Bolanos et al. Nov 1996 A
5575788 Baker et al. Nov 1996 A
5588432 Crowley Dec 1996 A
5588960 Edwards et al. Dec 1996 A
5588961 Leone et al. Dec 1996 A
5591199 Porter et al. Jan 1997 A
5595183 Swanson et al. Jan 1997 A
5599294 Edwards et al. Feb 1997 A
5599307 Bacher et al. Feb 1997 A
5599345 Edwards et al. Feb 1997 A
5599346 Edwards et al. Feb 1997 A
5601591 Edwards et al. Feb 1997 A
5607422 Smeets et al. Mar 1997 A
5609151 Mulier et al. Mar 1997 A
5624439 Edwards et al. Apr 1997 A
5630794 Lax et al. May 1997 A
5630812 Ellman et al. May 1997 A
5634899 Shapland et al. Jun 1997 A
5647868 Chinn Jul 1997 A
5666954 Chapelon et al. Sep 1997 A
5667488 Lundquist et al. Sep 1997 A
5672153 Lax et al. Sep 1997 A
5674191 Edwards et al. Oct 1997 A
5674287 Slepian et al. Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5683384 Gough et al. Nov 1997 A
5685839 Edwards et al. Nov 1997 A
5688266 Edwards et al. Nov 1997 A
5688490 Tournier et al. Nov 1997 A
5697281 Eggers et al. Dec 1997 A
5702438 Avitall Dec 1997 A
5707349 Edwards Jan 1998 A
5709224 Behl et al. Jan 1998 A
5709539 Hammer et al. Jan 1998 A
5715817 Stevens-Wright et al. Feb 1998 A
5718702 Edwards Feb 1998 A
5720718 Rosen et al. Feb 1998 A
5720719 Edwards et al. Feb 1998 A
5728066 Daneshvar Mar 1998 A
5728094 Edwards Mar 1998 A
5728144 Edwards et al. Mar 1998 A
5730719 Edwards Mar 1998 A
5732698 Swanson et al. Mar 1998 A
5733319 Neilson et al. Mar 1998 A
5738096 Ben-Haim Apr 1998 A
5738114 Edwards Apr 1998 A
5741225 Lax et al. Apr 1998 A
5743870 Edwards Apr 1998 A
5743904 Edwards Apr 1998 A
5746224 Edwards May 1998 A
5766234 Chen et al. Jun 1998 A
5769846 Edwards et al. Jun 1998 A
5769880 Truckai et al. Jun 1998 A
5772255 Osborne et al. Jun 1998 A
5779673 Roth et al. Jul 1998 A
5797903 Swanson et al. Aug 1998 A
5800378 Edwards et al. Sep 1998 A
5800482 Pomeranz et al. Sep 1998 A
5800484 Gough et al. Sep 1998 A
5807333 Osborne et al. Sep 1998 A
5810763 Feiring Sep 1998 A
5823197 Edwards Oct 1998 A
5827273 Edwards Oct 1998 A
5830213 Panescu et al. Nov 1998 A
5836314 Benderev et al. Nov 1998 A
5836874 Swanson et al. Nov 1998 A
5840076 Swanson et al. Nov 1998 A
5843016 Lugnani et al. Dec 1998 A
5843026 Edwards et al. Dec 1998 A
5843156 Slepian et al. Dec 1998 A
5860974 Abele Jan 1999 A
5865801 Houser Feb 1999 A
5871469 Eggers et al. Feb 1999 A
5871483 Jackson et al. Feb 1999 A
5891135 Jackson et al. Apr 1999 A
5921954 Mohr, Jr. et al. Jul 1999 A
5921982 Lesh et al. Jul 1999 A
5957920 Baker Sep 1999 A
5961513 Swanson et al. Oct 1999 A
5964755 Edwards Oct 1999 A
5964791 Bolmsjo Oct 1999 A
6002968 Edwards Dec 1999 A
6006755 Edwards Dec 1999 A
6009877 Edwards Jan 2000 A
6013053 Bower et al. Jan 2000 A
6015407 Rieb et al. Jan 2000 A
6044846 Edwards Apr 2000 A
6045496 Pacella et al. Apr 2000 A
6056744 Edwards May 2000 A
6077257 Edwards et al. Jun 2000 A
6091995 Ingle et al. Jul 2000 A
6092528 Edwards Jul 2000 A
6099526 Whayne et al. Aug 2000 A
6165172 Farley et al. Dec 2000 A
6168594 Lafontaine et al. Jan 2001 B1
6179824 Eggers et al. Jan 2001 B1
6190382 Ormsby et al. Feb 2001 B1
6193714 McGaffigan et al. Feb 2001 B1
6231514 Lowe et al. May 2001 B1
6231591 Desai May 2001 B1
6241753 Knowlton Jun 2001 B1
6254598 Edwards et al. Jul 2001 B1
6338726 Edwards et al. Jan 2002 B1
6409723 Edwards Jun 2002 B1
6419653 Edwards et al. Jul 2002 B2
6425853 Edwards Jul 2002 B1
6425877 Edwards Jul 2002 B1
6428538 Blewett et al. Aug 2002 B1
6463331 Edwards Oct 2002 B1
6470219 Edwards et al. Oct 2002 B1
6500175 Gough et al. Dec 2002 B1
6506189 Rittman, III et al. Jan 2003 B1
6613047 Edwards Sep 2003 B2
6692490 Edwards Feb 2004 B1
6743197 Edwards Jun 2004 B1
7022105 Edwards Apr 2006 B1
7184827 Edwards Feb 2007 B1
7291129 Li et al. Nov 2007 B2
7306591 Thomas et al. Dec 2007 B2
7326235 Edwards Feb 2008 B2
7722338 Nordell et al. May 2010 B2
8177781 Thomas et al. May 2012 B2
8353908 Edwards et al. Jan 2013 B2
8412318 Edwards et al. Apr 2013 B2
8465482 Thomas et al. Jun 2013 B2
20010031941 Edwards et al. Oct 2001 A1
20020156531 Felt et al. Oct 2002 A1
20100114087 Edwards et al. May 2010 A1
20120136407 Presthus May 2012 A1
20130282006 Thomas et al. Oct 2013 A1
Foreign Referenced Citations (28)
Number Date Country
3838840 May 1990 DE
4303882 Aug 1994 DE
0139607 May 1985 EP
0608609 Sep 2001 EP
2069063 Aug 1981 GB
2269538 Feb 1994 GB
02-121675 May 1990 JP
04-044739 Feb 1992 JP
04-246367 Sep 1992 JP
WO 8502779 Jul 1985 WO
WO 9101773 Feb 1991 WO
WO 9210142 Jun 1992 WO
WO 9308755 May 1993 WO
WO 9410925 May 1994 WO
WO 9421165 Sep 1994 WO
WO 9421178 Sep 1994 WO
WO 9422366 Oct 1994 WO
WO 9426178 Nov 1994 WO
WO 9508289 Mar 1995 WO
WO 9518575 Jul 1995 WO
WO 9519142 Jul 1995 WO
WO 9525472 Sep 1995 WO
WO 9600042 Jan 1996 WO
WO 9616606 Jun 1996 WO
WO 9629946 Oct 1996 WO
WO 9706857 Feb 1997 WO
WO 9801087 Jan 1998 WO
WO 9908614 Feb 1999 WO
Non-Patent Literature Citations (15)
Entry
Castell et al.; Gastroesophageal Reflux Disease: Current Strategies for Patient Management; Arch Fam Med; Apr. 1996; 5(4); pp. 221-227.
Dallemagne et al.; Laparoscopic Nissen Fundoplication: Preliminary Report; Surgical Laparoscopy & Endoscopy; Sep. 1991 1(3): 138-43.
Hinder et al.; The Technique of Laparosopic Nissen Fundoplication; Surgical Laparoscopy & Endoscopy; Sep. 1992. 2(3): 265-272.
Kaneko et al.; Physiological Laryngeal Pacemaker; Trans Am Soc Artif Intern Organs; May 1985; vol. XXXI; pp. 293-296.
Karlstrom et al; Ectopic jejunal pacemakers and enterogastric reflux after Roux gastrectomy: Effect of intestinal pacing; Surgery; Sep. 1989; 106(3); 486-495.
Kelly et al; Doudenal-gastric reflux and slowed gastric emptying by electrical pacing of the canine duodenal pacesetter potential; Gastroenterology; Mar. 1977; 72(3); 429-33.
Mugica et al.; Direct Diaphragm Stimulation; Jan. 1987; Pace; vol. 10; pp. 252-256.
Mugica et al.; Neurostimulation: An Overview, Chapter 21, Preliminary Test of a Muscular Diaphragm Pacing System on Human Patients; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1985; pp. 263-279.
Prior et al.; Treatment of Menorrhagia by Radiofrequency Heating; Int. J. Hyperthermia; Mar.-Apr. 1991; vol. 7; No. 2; pp. 213-220.
Rice et al.; Endoscopic Paranasal Sinus Surgery, Chapter 5, Functional Endoscopic Paranasal Sinus Surgery; The Technique of Messerklinger; Raven Press; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1988; pp. 75-102.
Rice et al.; Endoscopic Paranasal Sinus Surgery, Chapter 6, Total Endoscopic Sphenoethmoidectomy; The Technique of Wigand; Raven Press; (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date) 1988; pp. 103-125.
Slepian; Polymeric Endoluminal Paving and Sealing; Textbook of Interventional Cardiology; WB Saunders Publishing; pp. 647-670; 1990 (year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date).
Tissue; Electromagnetic Spectrum, The Visible Spectrum; Copyright 1996; updated Nov. 3, 1996. 1 page; retrieved online from: Science Hypermedia Home Page; http://www.scimedia.com/checm-ed/light/edm-spec.htm. (printed Mar. 30, 2011).
Urschel, J.D.; Complications of Antireflux Surgery; Am J Surg; Jul. 1993; 166(1); 68-70.
Edwards, Stuart; U.S. Appl. No. 12/698,841 entitled “Treatment of urinary incontinence and other disorders by application of energy and drugs,” filed Feb. 2, 2010.
Related Publications (1)
Number Date Country
20130197505 A1 Aug 2013 US
Divisions (1)
Number Date Country
Parent 11207677 Aug 2005 US
Child 12648249 US
Continuations (2)
Number Date Country
Parent 12648249 Dec 2009 US
Child 13717289 US
Parent 09356110 Jul 1999 US
Child 11207677 US
Continuation in Parts (1)
Number Date Country
Parent 08717612 Sep 1996 US
Child 09356110 US